|Registry of biomedical companies:
   [A] [B] [C] [D] [E] [F] [G] [H] [I] [J] [K] [L] [M] [N] [O] [P] [Q] [R] [S] [T] [U] [V] [W] [X] [Y] [Z] 586 active entries
6100, avenue Royalmount
Montreal, QC, H4P 2R2
REPLICor is a biopharmaceutical company developing a new antiviral drug that will revolutionize the treatment of patients with chronic hepatitis B and for patients with hepatitis D. This antiviral drug is currently being tested in clinical trials in Asia and Moldova to demonstrate its safety and activity in human patients. It is expected that our drug will also find important applications in the treatment of patients infected with influenza, RSV and CMV.
Last update of this entry: September 06, 2016